1-3 of 3
Marta Stanzani, MD, PhD
Close
Sort by
Journal Articles

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Carlo Finelli, MD, Cristina Clissa, MD, Matilde Y Follo, PhD, Marta Stanzani, MD PhD, Paolo Avanzini, Costanza Bosi, MD, Barbara Castagnari, MD, Anna Candoni, MD, Monica Crugnola, MD, Maria Benedetta Giannini, MD, Marco Gobbi, MD, Giovanna Leonardi, MD, Gian Matteo Rigolin, MD, Patrizia Tosi, MD, Giuseppe Visani, MD, Lucio Cocco, MD, Michele Cavo, MD, Domenico Russo, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4648.
https://doi.org/10.1182/blood.V124.21.4648.4648
Published: 2014
Journal Articles

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Matilde Y Follo, PhD, Carlo Finelli, Cristina Clissa, M.D., Sara Mongiorgi, PhD, Carmen Baldazzi, Marta Stanzani, MD, PhD, Michele Baccarani, MD, Lucio Cocco, MD
Journal: Blood
Blood (2013) 122 (21): 5227.
https://doi.org/10.1182/blood.V122.21.5227.5227
Published: 2013
Journal Articles

Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.

Mario Arpinati, MD, PhD, Marilina Amabile, maria Teresa Bochicchio, Angela Poerio, Giuseppe Bandini, Francesca Bonifazi, MD, Marta Stanzani, MD, PhD, Fausto Castagnetti, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, MD
Journal: Blood
Blood (2010) 116 (21): 1287.
https://doi.org/10.1182/blood.V116.21.1287.1287
Published: 2010